Navigation Links
The race toward an interferon free world: The current field of Hepatitis C Virus treatment research, including recent financial deals
Date:4/26/2013

NEW YORK, April 26, 2013 /PRNewswire/ -- Citeline®, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials has just published an exclusive whitepaper examining the current progress towards a remarkable improvement in the medical treatment for HCV.

(Logo: http://photos.prnewswire.com/prnh/20120917/NE75453LOGO

With news of the impending breakthrough in HCV treatment, Citeline reviews the current landscape of clinical trials and drugs in this competitive space as well as the recent history of HCV-related financial deals.  In addition the whitepaper takes a look at the timing of current Phase III trials evaluating all oral regimens to determine how long Gilead may be the sole player in this space.  

Based on information in Citeline's clinical trial intelligence tool, Trialtrove®, 83% of the 200 planned and ongoing Phase I-III clinical trials for pipeline HCV drugs (excluding vaccines) are being conducted by 10 companies; these 10 companies, including Bristol-Myers Squibb, Gilead, Merck and AbbVie, among others, are the focus of this report. Gilead leads in the number of Phase II trials and is conducting over twice as many as the next most active Phase II sponsor, Bristol-Myers Squibb.

According to Doro Shin , MPH, Citeline's Senior Analyst, Infectious & Genitourinary Diseases, "Gilead's lead in direct acting antiviral (DAA) agents for the treatment of HCV could lead to a shorter, oral, and interferon free treatment of the disease, with a dramatic reduction in unwanted side effects. This is truly a new era in HCV treatment. "

Moreover, in reviewing deals over the last five years we discovered between March 2008 and March 2013, there were a total of 18 HCV specific industry partnerships. In both years partnerships comprised of research and discovery and commercialization agreements occurred most frequently; however, three partnerships in 2012 also included licensing agreements. The complete report provides details of these partnership and M&A details including deal values.

"DAAs are clearly dominating in the HCV treatment field as evidenced by the clinical trial landscape and recent financial dealings," remarks Ms. Shin. "With these DAAs, the race is on toward the first interferon free HCV treatment regimen, but the contenders have entered themselves into different events to ensure that they get the gold."

To read this exclusive whitepaper - The race toward an interferon free world: The current field of HCV treatment research, including recent financial deals go to www.citeline.com/resource-center/whitepapers               

About Citeline
Citeline, Inc., an Informa company. Citeline is the world's most comprehensive source of real-time R&D and commercial intelligence featuring an unmatched data collection of global clinical trials, clinical trial investigator profiles, drug development pipelines and commercial intelligence.

Contact for Further Information
Sean McIntosh
Director of Marketing
Citeline Inc.
52 Vanderbilt Ave
7th Floor
New York, NY 10017
212-520-2741
sean.mcintosh@citeline.com 
www.citeline.com 


'/>"/>
SOURCE Citeline
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
3. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
4. Medical Marijuana Inc. and Canipa Holdings Drive Dixie X and CanChew Gum Toward EU Marketing Approval And Clinical Development
5. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
6. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
7. The Shift from Treatment to Prevention: A Drive towards Cutting Healthcare Costs
8. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
9. In Vitro Diagnostics Markets Grow at Double the Pace of Pharma Markets in Shift toward Globalization
10. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
11. Novartis signs on to support Malaria No Mores Power of One campaign to stride towards a future without malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the dentists ... dentistry is a fast-growing field as more patients are discovering the many different ways ... about the options currently available to them and which ones might work for their ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader ... led by Eastside Partners, with participation from existing investor Martin Ventures. The ... accelerate its technology and product roadmap. , “Jvion is experiencing significant ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on ... place for Tampa’s Best Places to Work. They were ranked in the Big Category, ... for our team,” says RMS Human Resources Manager Irene Miller. “We work hard to ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):